Your browser doesn't support javascript.
loading
Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
Ng, Siew C; Kamm, Michael A; Yeoh, Yun Kit; Chan, Paul K S; Zuo, Tao; Tang, Whitney; Sood, Ajit; Andoh, Akira; Ohmiya, Naoki; Zhou, Yongjian; Ooi, Choon Jin; Mahachai, Varocha; Wu, Chun-Ying; Zhang, Faming; Sugano, Kentaro; Chan, Francis K L.
Afiliación
  • Ng SC; Center for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong, China siewchienng@cuhk.edu.hk.
  • Kamm MA; Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Yeoh YK; St Vincent's Hospital and University of Melbourne, Melbourne, Victoria, Australia.
  • Chan PKS; Center for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong, China.
  • Zuo T; Department of Microbiology and LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Tang W; Center for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong, China.
  • Sood A; Department of Microbiology and LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Andoh A; Center for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong, China.
  • Ohmiya N; Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Zhou Y; Center for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong, China.
  • Ooi CJ; Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Mahachai V; Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
  • Wu CY; Department of Medicine, Shiga University of Medical Science, Otsu, Japan.
  • Zhang F; Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.
  • Sugano K; Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
  • Chan FKL; Gleneagles Medical Centre and Duke-NUS Medical School, Singapore, Singapore.
Gut ; 69(1): 83-91, 2020 01.
Article en En | MEDLINE | ID: mdl-31611298
ABSTRACT

OBJECTIVE:

The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice.

DESIGN:

Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research.

RESULTS:

16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases.

CONCLUSION:

FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Microbiota Fecal Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Gut Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Microbiota Fecal Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Gut Año: 2020 Tipo del documento: Article País de afiliación: China